Eltrombopag is expected to improve trilineage blood cells and decrease transfusion frequency based on the result from the previous study in patients with severe AA. This study will use the hematologic response rate, defined as the proportion of subjects showing improvement in at least one of the three blood cell lineages or a decrease in blood transfusion volume, as the primary endpoint.